Trial Profile

GRemubamab ErAdication Trial (GREAT-2) A phase 2 trial of gremubamab compared to placebo in participants with bronchiectasis and chronic Pseudomonas aeruginosa infection

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gremubamab (Primary)
Indications Bronchiectasis; Pseudomonal infections
Focus Therapeutic Use
Acronyms GREAT-2

Most Recent Events

13 May 2025 According to AstraZeneca media release, data from the study will be presented at at the American Thoracic Society (ATS) International Conference, in San Francisco, CA from May 16 to 21, 2025.
06 Dec 2023 Status changed from recruiting to active, no longer recruiting.
06 Dec 2023 Planned number of patients changed from 90 to 60.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com